Vinge Logotype
SvenskaEnglish 18D7E0DE-2035-40AE-A740-8F45A358A8F4 Login
  1. Home
  2. Mandates
  3. Vinge has advised the lead investor ARCH Venture Partners in Moleculent’s $26 million Series A financing
Mandate

Vinge has advised the lead investor ARCH Venture Partners in Moleculent’s $26 million Series A financing

June 19, 2024

Moleculent AB, a company pioneering technology to study the communication between cells in human tissue, has closed its oversubscribed $26 million Series A financing. The round was led by ARCH Venture Partners and co-led by Eir Ventures with participation from the company’s existing investors.

ARCH Venture Partners creates and invests in groundbreaking life science and technology companies. The firm is a recognized leader in commercializing technologies developed at academic institutions, corporate research groups and national laboratories.

The Vinge team primarily consisted of Johan Larsson, Maria Dahlin Kolvik, Stojan Arnerstål, David Olander, Johan Gavelin, Olof Löfvenberg and Alice Göransson.

Related

Vinge advises Röko AB (publ) in connection with the establishment of its MTN programme

 Vinge has advised Röko AB (publ) ("Röko") on the establishment of a medium-term note programme (the "MTN Programme") with a framework amount of SEK 5 billion.
November 13, 2026

Vinge advises Telavox on the sale of its Nordic customer base to Telia

 Vinge has advised Telavox AB (“Telavox”) on the sale of Telavox’s Nordic customer base for business services to Telia Company AB (“Telia”). The customer base comprises approximately 24,000 business customers and 325,000 end users in Sweden, Denmark, Finland, and Norway. The purchase price amounts to SEK 3.8 billion plus a potential additional earn-out.
November 13, 2026

Vinge has advised Course Corrected VC on the establishment of Course Corrected VC Fund II

 Vinge has advised Course Corrected VC on the establishment and structuring of their second fund, Course Corrected VC Fund II (the “Fund”).
November 12, 2026